Programmed death-ligand 1 expression and use of immune checkpoint inhibitors among patients with advanced non-small-cell lung cancer in a resource-limited country

• Main Authors: How, Soon Hin, Tho, Lye Mun, Liam, Chong Kin, Hasbullah, Harissa H., Ho, Gwo Fuang, Nor, Ibtisam Muhammad, Poh, Mau Ern, Ho, Kean Fatt, Thiagarajan, Muthukkumaran, Samsudin, Azlina, Omar, Azza, Ong, Choo Khoon, Pang, Yong Kek, Soon, Sing Yang
• Format: Article
• Published: Wiley Open Access 2022
• Subjects: RC0254 Neoplasms. Tumors. Oncology (including Cancer); RD Surgery
• Online Access: http://eprints.um.edu.my/42216/

Introduction Immune checkpoint inhibitor (ICI) therapy is an established treatment for advanced non-small-cell lung cancer (NSCLC) and programmed death ligand-1 (PD-L1) expression is a recognized biomarker to determine response to therapy. We retrospectively analyzed NSCLC patients in the Malaysia L...